Astrazeneca Ab

Ciba-geigy Corporation

Martin Nylof

Annika Kers

Britt-Marie Swahn

Stefan Von Berg

Karin Kolmodin

Laszlo Rakos

Peter Soderman

Sofia Karlstrom

Lars Sandberg

Liselotte Ohberg

Gabor Csjernyik

Fernando Sehgelmeble

Andrew Griffin

Shawn Donald Johnstone

Per Engelhardt

Katarina Beierlein

Jan-Erik Nystrom

Denis Labrecque

Yevgeni Besidski

Inger Kers

Paul Jones

Jan Vagberg

Karin Skogholm

Bjorn Elman

Mikael Sellen

The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A&#x3b2;-related pathologies such as Down's syndrome, &#x3b2;-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ('mild cognitive impairment'), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

Compounds and their use as BACE inhibitors

The present invention relates to new compounds or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

Compounds

A process for the production of a 5-7 membered ring cyclic sulfonium salt compound, including a 5-7 membered ring cyclic sulfonium salt compound having a non-nucleophilic anion, is described. Members of the latter group are potentially useful as initiators for cationic polymerizations. The process comprises reacting a 1.4-, 1.5-, or 1.6-diol compound or a 5-7 membered ring cyclic ether compound with a mercapto compound and a strong protonic acid yielding the cyclic sulfonium salt compound. Some compounds described are also novel compounds per se.

Process for the production of cyclic sulfonium salts

Growing community of inventors

Sodertalje, Sweden

Martin Nylof